Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates

• Published in: bioRxiv 2021-03
• Main Authors: Francica, Joseph R, Flynn, Barbara J, Foulds, Kathryn E, Noe, Amy T, Werner, Anne P, Moore, Ian N, Gagne, Matthew, Johnston, Timothy S, Tucker, Courtney, Davis, Rachel L, Flach, Britta, Sarah O’connell, Andrew, Shayne F, Lamb, Evan, Flebbe, Dillon R, Nurmukhambetova, Saule T, Donaldson, Mitzi M, Todd, John-Paul M, Alex Lee Zhu, Atyeo, Caroline, Fischinger, Stephanie, Gorman, Matthew J, Shin, Sally, Edara, Venkata Viswanadh, Floyd, Katharine, Lai, Lilin, Tylor, Alida, Mccarthy, Elizabeth, Lecouturier, Valerie, Ruiz, Sophie, Berry, Catherine, Tibbitts, Timothy, Andersen, Hanne, Cook, Anthony, Dodson, Alan, Pessaint, Laurent, Alex Van Ry, Koutsoukos, Marguerite, Gutzeit, Cindy, I-Ting, Teng, Zhou, Tongqing, Li, Dapeng, Haynes, Barton F, Kwong, Peter D, Mcdermott, Adrian, Lewis, Mark G, Fu, Tong Ming, Chicz, Roman, Van Der Most, Robbert, Corbett, Kizzmekia S, Suthar, Mehul S, Alter, Galit, Roederer, Mario, Sullivan, Nancy J, Douek, Daniel C, Graham, Barney S, Casimiro, Danilo, Seder, Robert A
• Format: Article
• Language: English
• Subjects: Antibodies; Clinical trials; Coronaviruses; Fc receptors; Immunoglobulin G; Immunology; Serology; Severe acute respiratory syndrome coronavirus 2; Spike protein; Trimers; Vaccines; Viral infections
• ISSN: 2692-8205
• DOI: 10.1101/2021.03.02.433390

Abstract Adjuvanted soluble protein vaccines have been used extensively in humans for protection against various viral infections based on their robust induction of antibody responses. Here, soluble prefusion-stabilized spike trimers (preS dTM) from the severe acute respiratory syndrome coronavirus (SARS-CoV-2) were formulated with the adjuvant AS03 and administered twice to nonhuman primates (NHP). Binding and functional neutralization assays and systems serology revealed that NHP developed AS03-dependent multi-functional humoral responses that targeted multiple spike domains and bound to a variety of antibody FC receptors mediating effector functions in vitro. Pseudovirus and live virus neutralizing IC50 titers were on average greater than 1000 and significantly higher than a panel of human convalescent sera. NHP were challenged intranasally and intratracheally with a high dose (3×106 PFU) of SARS-CoV-2 (USA-WA1/2020 isolate). Two days post-challenge, vaccinated NHP showed rapid control of viral replication in both the upper and lower airways. Notably, vaccinated NHP also had increased spike-specific IgG antibody responses in the lung as early as 2 days post challenge. Moreover, vaccine-induced IgG mediated protection from SARS-CoV-2 challenge following passive transfer to hamsters. These data show that antibodies induced by the AS03-adjuvanted preS dTM vaccine are sufficient to mediate protection against SARS-CoV-2 and support the evaluation of this vaccine in human clinical trials. Competing Interest Statement All authors have declared the following interests: VL, TB, CB, SR, TMF, DC, RC are Sanofi Pasteur employees and may hold stock. MK, RvdM, and CG are employees of the GSK group of companies and report ownership of GSK shares.